Last update 28 Jun 2025

Elranatamab

Overview

Basic Info

Drug Type
Bispecific T-cell Engager (BiTE)
Synonyms
Elranatamab (USAN), elranatamab-bcmm, PF-06863135
+ [6]
Action
modulators, stimulants
Mechanism
BCMA modulators(B-cell maturation protein modulators), CD3 stimulants(T cell surface glycoprotein CD3 stimulants)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
United States (14 Aug 2023),
RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Conditional marketing approval (China), Conditional marketing approval (European Union), Fast Track (European Union), Priority Review (China)
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D12058--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Multiple Myeloma
United States
14 Aug 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Relapse multiple myelomaPhase 3
United States
08 Feb 2024
Relapse multiple myelomaPhase 3
Japan
08 Feb 2024
Relapse multiple myelomaPhase 3
Argentina
08 Feb 2024
Relapse multiple myelomaPhase 3
Australia
08 Feb 2024
Relapse multiple myelomaPhase 3
Belgium
08 Feb 2024
Relapse multiple myelomaPhase 3
Brazil
08 Feb 2024
Relapse multiple myelomaPhase 3
Canada
08 Feb 2024
Relapse multiple myelomaPhase 3
Czechia
08 Feb 2024
Relapse multiple myelomaPhase 3
Denmark
08 Feb 2024
Relapse multiple myelomaPhase 3
Finland
08 Feb 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
47
ELRA 76 mg QW
jegvnwgimv(lpyfgssgbb) = 100% pts reported any grade treatment-emergent adverse events gkevknyenm (ifilvytlmz )
Positive
30 May 2025
Not Applicable
Multiple Myeloma
LDH | ferritin | cytopenia
43
(BOSS program)
ymcqkccjco(jcnparubrw) = vzfesekkxo wxulziwvht (ujasdhoeio )
Positive
30 May 2025
(iSUD program)
ymcqkccjco(jcnparubrw) = dyfxdyefgy wxulziwvht (ujasdhoeio )
Not Applicable
-
vupqvvqypo(pmureejgpx) = bduffjmcwd cnspvfybbv (osypdvtfpk )
Positive
30 May 2025
vupqvvqypo(pmureejgpx) = dfudxnlxhm cnspvfybbv (osypdvtfpk )
Phase 3
BCMA-CD3
37
Elranatamab + Daratumumab + Lenalidomide
ivruykzwsc(enlelzkshc) = 1 case of G2 ICANS was reported gspmqbqzcr (zonbpziyez )
Positive
30 May 2025
Phase 3
-
37
ELRANATAMAB + DARATUMUMAB + LENALIDOMIDE (EDR)
wyalxqelhh(atgwvdragp) = There was one G5 Candida pneumonia yyypsofgmx (ersuabryre )
Positive
14 May 2025
Phase 2
184
lawjgvdyma(usmbdkwnmv): least square mean difference = -11.22 (95% CI, -19.48 to -2.9)
Positive
14 May 2025
Physician’s choice of therapy
Phase 2
47
ELRANATAMAB (ELRA)
trjzztkzcy(fsqngqyzhw) = 100% of patients experienced any grade treatment-emergent adverse events wscdvkoroo (hdlcdwwpmk )
Positive
14 May 2025
Not Applicable
14
rabevgjrap(cgkhzonmkb) = One patient died of multi-organ failure due to progressive myeloma and concomitant infection following a single cycle elranatamab slweylwrtb (nueruhvcuc )
-
14 May 2025
Immunoglobulin replacement therapy
Phase 2
40
jdjmplelbw(qhilateoeh) = xfrckkzlyi qvrnkitnkv (eoknhwsmbo, 59 - 89)
-
14 May 2025
Phase 2
123
Elranatamab arm
unpipyhcft(ovorpiiyyr) = hmplqdeizl rfrmrxmhiu (ytanntcbnj, NE)
Positive
14 May 2025
(RW cohort)
unpipyhcft(ovorpiiyyr) = utgkgmaoar rfrmrxmhiu (ytanntcbnj, 4.44 - 9.46)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free